Drug Detail

Information about IDRX-42

Generic Name
IND
 IDRX-42
Brand Name (US)
Manufacturer
 IDRx, Inc.
Drug Type
Delivery
 Oral
Approval Status
Indications
Overall Strategy
 Inhibit KIT/PDGFRa
Strategy
 Block KIT/PDGFRA
Drug Category
 KIT/PDGFRA inhibitor

Links

 

 The Potential of c-KIT Kinase inhibitors in Cancer Treatment
   

 

 MedCity News 8/2/2022: Aiming to bring drug combos into earlier lines of cancer therapy, IDRx lands $122M
   

 

 IDRx Presents Preliminary Clinical Data from Ongoing Phase 1 StrateGIST Study at CTOS 2023 Supporting Best-in-Class Potential of IDRX-42 in Patients with GIST
   

Trials of this drug

  

 A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) [Study ID: StrateGIST1]
   

Trial results
  IDRx Presents Preliminary Clinical Data from Ongoing Phase 1 StrateGIST Study at CTOS 2023 Supporting Best-in-Class Potential of IDRX-42 in Patients with GIST
   
  CTOS 2023 Schoffski poster
   

Search for this drug/combination in:

ClinicalTrials.gov

ASCO

Pubmed